Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Phase I Trial of Intravenous Administration of Vesicular Stomatitis Virus Genetically Engineered to Express Thyroidal Sodium Iodide Symporter (NIS) and Human Interferon Beta (hIFNb), in Patients With Metastatic or Recurrent Endometrial Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT03120624
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:28:30.532443+00:00
Published At
2024-10-29T00:00:00+00:00
Record Updated At
2026-02-04
Results Posted At
2024-10-29
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Metastatic Endometrial Carcinoma", "Recurrent Endometrial Adenocarcinoma", "Recurrent Endometrial Carcinoma", "Recurrent Endometrial Clear Cell Adenocarcinoma", "Recurrent Endometrial Endometrioid Adenocarcinoma", "Recurrent Endometrial Mixed Cell Adenocarcinoma", "Recurrent Endometrial Serous Adenocarcinoma", "Recurrent Endometrial Undifferentiated Carcinoma", "Recurrent Uterine Corpus Carcinosarcoma", "Stage IV Uterine Corpus Cancer AJCC v7"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-02-04"
protocolSection.identificationModule.nctId
"NCT03120624"
protocolSection.identificationModule.officialTitle
"Phase I Trial of Intravenous Administration of Vesicular Stomatitis Virus Genetically Engineered to Express Thyroidal Sodium Iodide Symporter (NIS) and Human Interferon Beta (hIFNb), in Patients With Metastatic or Recurrent Endometrial Cancer"
protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2024-10-29"

Study condition terms

  • Metastatic Endometrial Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Endometrial Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Endometrial Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Endometrial Clear Cell Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Endometrial Endometrioid Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Endometrial Mixed Cell Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Endometrial Serous Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Endometrial Undifferentiated Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Uterine Corpus Carcinosarcoma (protocolSection.conditionsModule.conditions)
  • Stage IV Uterine Corpus Cancer AJCC v7 (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.